Vivus (VVUS): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Vivus ( VVUS) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.3%. By the end of trading, Vivus fell 30 cents (-2.6%) to $11.43 on light volume. Throughout the day, 2.7 million shares of Vivus exchanged hands as compared to its average daily volume of four million shares. The stock ranged in price between $11.35-$12.02 after having opened the day at $11.95 as compared to the previous trading day's close of $11.73. Other companies within the Drugs industry that declined today were: Dynavax Technologies Corporation ( DVAX), down 5.5%, Telik ( TELK), down 4.8%, Biocryst Pharmaceuticals ( BCRX), down 4.7%, and Biostar Pharmaceuticals ( BSPM), down 4.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

VIVUS, Inc., a biopharmaceutical company, is developing therapies to address obesity, sleep apnea, diabetes, and male sexual health. Its lead investigational product, Qnexa, has completed Phase three clinical trials for the treatment of obesity. Vivus has a market cap of $1.18 billion and is part of the health care sector. The company has a P/E ratio of -11.8, below the S&P 500 P/E ratio of 17.7. Shares are up 20.3% year to date as of the close of trading on Wednesday. Currently there are six analysts that rate Vivus a buy, one analyst rates it a sell, and four rate it a hold.

TheStreet Ratings rates Vivus as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share.

On the positive front, MAP Pharmaceuticals ( MAPP), up 20.3%, Star Scientific ( STSI), up 13.6%, Rosetta Genomics ( ROSG), up 12.9%, and Coronado Biosciences ( CNDO), up 12.6%, were all gainers within the drugs industry with Abbott Laboratories ( ABT) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.

null

More from Markets

Russia Risk: What You Need to Know About the New 'Reset'

Russia Risk: What You Need to Know About the New 'Reset'

Stocks Show Signs of Life During Fed Chair Powell's Testimony on Capitol Hill

Stocks Show Signs of Life During Fed Chair Powell's Testimony on Capitol Hill

UnitedHealth CEO: We See More Tailwinds Than Headwinds

UnitedHealth CEO: We See More Tailwinds Than Headwinds

Jim Cramer: Bank of America Expects 4% Economic Growth in Q2

Jim Cramer: Bank of America Expects 4% Economic Growth in Q2

Jim Cramer Reacts to Lloyd Blankfein's Retirement at Goldman Sachs

Jim Cramer Reacts to Lloyd Blankfein's Retirement at Goldman Sachs